Skip to main content

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Volume 18, Issue 3, May 2021 - First Report Managed Care

Department

News Connection
05/28/2021
Neurologic toxicities from treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) increased total health care costs more than $70,000 on average for US patients, according to a study published recently in American Health &...
Neurologic toxicities from treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) increased total health care costs more than $70,000 on average for US patients, according to a study published recently in American Health &...
Neurologic toxicities from...
05/28/2021
First Report Managed Care

Advertisement

Advertisement

Advertisement